Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; Brown, J. R.; McKay, R. R.; Merchan, J. R.; Srinivas, S.; Shetty, A.; Moreno, B. H.; Davis, G.; Wirtz, H.; Zhu, Y.; Milowsky, M. I. |
| Abstract Title: | Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1139 |
| End Page: | S1140 |
| Language: | English |
| ACCESSION: | WOS:001326612902583 |
| DOI: | 10.1016/j.annonc.2024.08.2053 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1968P -- Source: Wos |
